<DOC>
	<DOCNO>NCT02712424</DOCNO>
	<brief_summary>DAR-901 booster vaccine placebo administer adolescent Tanzania prim BCG determine immunization reduces risk TB infection</brief_summary>
	<brief_title>DAR-901 TB Booster Vaccine Prevent TB Adolescents</brief_title>
	<detailed_description>DAR-901 whole cell booster vaccine prevent TB infection adolescent ( `` DAR-PIA '' ) This Phase II , 3-injection , randomize , control trial DAR-901 conduct 13-15 year old adolescent Tanzania previously immunize BCG . DAR-901 whole cell inactivate non-tuberculous mycobacterial vaccine manufacture Master Cell Bank SRL-172 use successful Phase III DarDar Trial Tanzania . The goal establish safety efficacy DAR-901 prevent infection TB . The 1 mg dose select current Phase I dose-escalation trial DAR-901 US conduct Dartmouth Aeras . The 1 mg dose corresponds dose SRL 172 use DarDar Trial . All subject screen T-spotÂ® IGRA ( Oxford Immunotec , Oxford , England ) evidence TB infection . All screened subject structure interview identify risk factor TB infection ( =positive IGRA ) . IGRA-positive subject refer evaluation enter immunization phase trial . It estimate 1000 adolescent need screen identify total 650 IGRA-negative adolescent immunization phase trial . Subjects randomize 1:1 DAR-901 saline control 0 , 2 4 month . Doses administer intradermal ( ID ) injection deltoid area . IGRA test repeat dose 2 , 14 month , 24 month . The two year study schedule begin first quarter 2016 Dar e Salaam , fund GHIT-Japan direct Geisel School Medicine Dartmouth ( PI , F. von Reyn ) collaborator Muhimbili University Health Allied Sciences ( MUHAS ) Tanzania Tokyo Medical Dental University Japan .</detailed_description>
	<mesh_term>Tuberculosis</mesh_term>
	<criteria>Negative IGRA baseline Pregnancy , serious underlie disease</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>15 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Vaccine</keyword>
</DOC>